Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation

The direct factor-Xa inhibitor apixaban is approved e.g. for the prevention of stroke in patients with atrial fibrillation (AF). Although routine monitoring of apixaban therapy is currently not recommended, selective monitoring could be useful to optimize efficacy and safety in certain clinical situations. We studied the exposure and effect of apixaban using different laboratory methods in a clinical setting with a well-defined cohort of AF patients.
Source: Thrombosis Research - Category: Hematology Authors: Tags: Regular Article Source Type: research